Soleil Securities upgrades Sepracor (SEPR) to Buy, Says Far More Attractive Takeover Target

Soleil Securities upgrades Sepracor (Nasdaq: SEPR) from Hold to Buy with a $67 price target citing improving fundamentals driven by an awakening in the previously sluggish insomnia market, a surge in Xopenex HFA (inhaler) prescriptions, and an apparent delay to Xopenex UDV reimbursement cuts.

Analyst Matt Renna of Neponset Equity Research said, We believe now a far more attractive consolidation target and see the possible addition of SEPR's portfolio to the bag of a larger player as a means to improve sales force efficiency."